Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 10/20 | 0.43 |
| ▸ | JAK2 | O60674 | 5/20 | 0.43 |
| ▸ | JAK3 | P52333 | 4/20 | 0.41 |
| ▸ | TYK2 | P29597 | 2/20 | 0.38 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 4/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 5/20 | 0.34 |
| ▸ | CSF1R | P07333 | 4/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3116796 | 0.86 | JAK1 (0.44) | JAK1JAK2JAK3TYK2PAK1 | |
| SCHEMBL13268016 | 0.84 | BRD4 (0.51) | JAK1JAK2JAK3TYK2PAK1 | |
| SCHEMBL14553232 | 0.82 | JAK1 (0.46) | JAK1JAK2JAK3TYK2PAK1 | |
| SCHEMBL12854480 | 0.81 | JAK1 (0.43) | JAK1JAK2JAK3TYK2PAK1 | |
| SCHEMBL14553235 | 0.80 | JAK1 (0.44) | JAK1JAK2JAK3TYK2PAK1 | |
| SCHEMBL3118461 | 0.80 | JAK1 (0.48) | JAK1JAK2JAK3TYK2PAK1 | |
| SCHEMBL3120192 | 0.79 | JAK1 (0.46) | JAK1JAK2JAK3TYK2PAK1 | |
| SCHEMBL3114853 | 0.78 | SYK (0.48) | JAK1JAK2JAK3TYK2PAK1 | |
| SCHEMBL3103946 | 0.77 | JAK1 (0.46) | JAK1JAK2JAK3TYK2PAK1 | |
| SCHEMBL13268027 | 0.76 | BRD4 (0.58) | JAK1JAK2JAK3BRD4EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130012501-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2013-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012501-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | PLK1, TK1, DTYMK | JAK1 567/4885JAK2 854/4885JAK3 1186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.